[Hepatitis delta: Clinical aspects and therapeutic perspectives] - Université Claude Bernard Lyon 1 Access content directly
Journal Articles La Presse Médicale Year : 2017

[Hepatitis delta: Clinical aspects and therapeutic perspectives]


HDV prevalence must not be disregarded, as the virus is associated with a higher severity of hepatic disease. All HBV carriers should be tested for HDV as well, at least once during the disease history, and in case of worsening of a chronic HBV hepatitis. Diagnosis should rely on anti-HDV antibody testing, and confirmed by HDV RNA detection and quantification by RT-qPCR. The only treatment available is pegylated alpha interferon. Optimal duration of treatment has not yet been proven, and relapses are common. Disease follow-up should be carried on even when SVR is obtained, in order to track late viral relapses, and fibrosis complications (such as HCC screening)
No file

Dates and versions

hal-01795725 , version 1 (18-05-2018)



Dulce Alfaiate, Clothilde Miaglia, Fabien Zoulim. [Hepatitis delta: Clinical aspects and therapeutic perspectives]. La Presse Médicale, 2017, 46, pp.271-281. ⟨10.1016/j.lpm.2016.10.013⟩. ⟨hal-01795725⟩
30 View
0 Download



Gmail Facebook X LinkedIn More